Universe Pharmaceuticals (UPC) Receivables - Other (2021 - 2025)

Universe Pharmaceuticals (UPC) has 5 years of Receivables - Other data on file, last reported at $2.3 billion in Q3 2025.

• For the quarter ending Q3 2025, Receivables - Other fell 35.98% year-over-year to $2.3 billion; the trailing twelve-month figure through Sep 2025 stood at $2.3 billion (down 35.98% YoY), and the FY2025 full-year result was -$3.3 billion, down 192.62% from the prior year.
• Receivables - Other fell to $2.3 billion in Q3 2025, from $3.6 billion in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $3.6 billion in Q3 2024 to a low of $236982.0 in Q3 2021.
• A 5-year average of $1.2 billion and a median of $1.9 million in 2023 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other jumped 185421.16% in 2024 and plunged 35.98% in 2025, its largest moves.
• Tracing UPC's Receivables - Other over 5 years: stood at $236982.0 in 2021, then soared by 50.34% to $356290.0 in 2022, then jumped by 438.96% to $1.9 million in 2023, then jumped by 185421.16% to $3.6 billion in 2024, then sank by 35.98% to $2.3 billion in 2025.
• Business Quant data shows UPC's Receivables - Other at $2.3 billion in Q3 2025, $3.6 billion in Q3 2024, and $1.9 million in Q3 2023.